Artificial Intelligence Within Pharmacovigilance: A Means to Identify Cognitive Services and the Framework for Their Validation.


Journal

Pharmaceutical medicine
ISSN: 1179-1993
Titre abrégé: Pharmaceut Med
Pays: New Zealand
ID NLM: 101471195

Informations de publication

Date de publication:
04 2019
Historique:
entrez: 15 1 2020
pubmed: 15 1 2020
medline: 28 4 2020
Statut: ppublish

Résumé

Pharmacovigilance (PV) detects, assesses, and prevents adverse events (AEs) and other drug-related problems by collecting, evaluating, and acting upon AEs. The volume of individual case safety reports (ICSRs) increases yearly, but it is estimated that more than 90% of AEs go unreported. In this landscape, embracing assistive technologies at scale becomes necessary to obtain a higher yield of AEs, to maintain compliance, and transform the PV professional work life. The aim of this study was to identify areas across the PV value chain that can be augmented by cognitive service solutions using the methodologies of contextual analysis and cognitive load theory. It will also provide a framework of how to validate these PV cognitive services leveraging the acceptable quality limit approach. The data used to train the cognitive service were an annotated corpus consisting of 20,000 ICSRS from which we developed a framework to identify and validate 40 cognitive services ranging from information extraction to complex decision making. This framework addresses the following shortcomings: (1) needing subject-matter expertise (SME) to match the artificial intelligence (AI) model predictions to the gold standard, commonly referred to as 'ground truth' in the AI space, (2) ground truth inconsistencies, (3) automated validation of prediction missing context, and (4) auto-labeling causing inaccurate test accuracy. The method consists of (1) conducting contextual analysis, (2) assessing human cognitive workload, (3) determining decision points for applying artificial intelligence (AI), (4) defining the scope of the data, or annotated corpus required for training and validation of the cognitive services, (5) identifying and standardizing PV knowledge elements, (6) developing cognitive services, and (7) reviewing and validating cognitive services. By applying the framework, we (1) identified 51 decision points as candidates for AI use, (2) standardized the process to make PV knowledge explicit, (3) embedded SMEs in the process to preserve PV knowledge and context, (4) standardized acceptability by using established quality inspection principles, and (5) validated a total of 126 cognitive services. The value of using AI methodologies in PV is compelling; however, as PV is highly regulated, acceptability will require assurances of quality, consistency, and standardization. We are proposing a foundational framework that the industry can use to identify and validate services to better support the gathering of quality data and to better serve the PV professional.

Identifiants

pubmed: 31933254
doi: 10.1007/s40290-019-00269-0
pii: 10.1007/s40290-019-00269-0
doi:

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109-120

Références

Arch Intern Med. 2007 Sep 10;167(16):1752-9
pubmed: 17846394
J Am Med Inform Assoc. 2009 May-Jun;16(3):328-37
pubmed: 19261932
Drug Saf. 2018 Dec;41(12):1355-1369
pubmed: 30043385
PDA J Pharm Sci Technol. 2016 Jul-Aug;70(4):392-408
pubmed: 27091885
Drug Saf. 2017 Nov;40(11):1075-1089
pubmed: 28643174
Clin Ther. 2016 Dec;38(12):2514-2525
pubmed: 27913029
Pharmaceut Med. 2018;32(6):391-401
pubmed: 30546259
J Biomed Inform. 2015 Apr;54:202-12
pubmed: 25720841

Auteurs

Ruta Mockute (R)

Celgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA. Rmockute@celgene.com.

Sameen Desai (S)

Celgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA.

Sujan Perera (S)

IBM Watson Health, Almaden Research Center, San Jose, CA, USA.

Bruno Assuncao (B)

Celgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA.

Karolina Danysz (K)

Celgene Corporation, Boudry, Switzerland.

Niki Tetarenko (N)

Celgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA.

Darpan Gaddam (D)

Celgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA.

Danielle Abatemarco (D)

Celgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA.

Mark Widdowson (M)

Celgene Corporation, Stockley Park, UK.

Sheryl Beauchamp (S)

Celgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA.

Salvatore Cicirello (S)

Celgene Corporation, Boudry, Switzerland.

Edward Mingle (E)

Celgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH